EGFR kinase inhibitors including gefitinib and erlotinib exert potent therapeutic efficacy in non-small cell lung cancers harboring EGFR activating mutations. However, most patients ultimately develop resistance to these drugs. Here we report a novel mechanism of acquired resistance to EGFR tyrosine kinase inhibitors and the reversal of which could improve clinical outcomes. In erlotinib-resistant lung cancer cells harboring activating EGFR mutations that we established, there was increased expression of Src, integrinβ1, α2, and α5 along with enhanced cell adhesion activity. Interestingly, RNAi-mediated silencing of integrinβ1 restored erlotinib sensitivity and reduced activation of Src and Akt after erlotinib treatment. Further, Src silencing inhibited Akt phosphorylation and cell growth, with this inhibitory effect further augmented by erlotinib treatment. Increased expression of integrinβ1, α5, and/or α2 was also observed in refractory tumor samples from lung cancer patients treated with erlotinib and/or gefitinib.
Introduction
Patients with non-small cell lung cancer (NSCLC) harboring activating somatic mutations in the epidermal growth factor receptor (EGFR) gene show dramatic clinical responses. Of the somatic mutations, in-frame deletions in exon 19 (del E746-A750) and the L858R point mutation are most commonly observed in NSCLC [1] . These EGFR mutations are closely associated with sensitivity to EGFR tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib. Both gefitinib and erlotinib have shown to improve progression-free survival as compared to chemotherapy alone when given as first-line treatment for patients with NSCLCs harboring activating EGFR mutations [2] [3] [4] [5] [6] .
However, one of the serious problems encountered during clinical treatment with EGFR-TKI is the appearance of drug-resistant tumors [7] . Well-characterized mechanisms for the acquired resistance to EGFR-TKIs include the T790M mutation in exon 20 of the EGFR-TK domain [8, 9] and Met amplification [10] . Furthermore, the loss of PTEN and increased expression of MAPK, ABCG2, IGF1R, and TGF-β have also been reported [7, 11, 12] . In addition to these well-characterized mechanisms, further elucidation of novel mechanisms for acquired drug resistance is essential for the development of personalized therapeutics and strategies to circumvent drug resistance.
In our laboratory, we have established various drug-resistant cell lines from human 
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Integrinβ1 contributes to EGFR-TKI resistance in NSCLC lung cancer cell lines harboring activating EGFR mutations by selecting for resistance to EGFR-TKIs [13] . Previously we have reported the loss of PTEN expression with the loss of nuclear translocation of EGR-1, a transcription factor responsible for PTEN gene expression, in gefitinib resistant clones [14] [15] [16] . We also reported that either the complete or partial loss of the activated EGFR gene allele could also result in the acquisition of erlotinib resistance [17] . In this present study, we further established erlotinib-resistant clones by step-wise selection following exposure to erlotinib and observed enhanced expression and activation of integrinβ1 and Src. Herein, we present a novel bypass mechanism through which the integrinβ1/Src/Akt signaling may play a pivotal role in the acquisition of erlotinib resistance in lung cancer cells. Organization, Kyushu Cancer Center, Japan, and 11-18 cells are provided by Dr. K Nakagawa, Kinki University, Japan. These cells and the resistant clones were cultured in RPMI medium supplemented with 10% fetal bovine serum in an atmosphere of 5% CO 2 [14, 18] . Cells were routinely confirmed to be free of mycoplasma contamination using myco sensor QPCR Assay kits (Agilent Technologies). Cells were transiently transfected with cDNA using Lipofectamine LTX, PLus reagent and Opti-MEM medium (Invitrogen) according to the manufacturer's recommendations. Cells were transfected with small interfering RNA (siRNA) duplexes using Lipofectamine RNAiMAX and Opti-MEM medium (Invitrogen) according to the manufacturer's recommendations. Reagents are described in Supplementary material and methods.
Cytotoxicity assays
Exponentially growing cell suspensions were seeded into each well and the following day the indicated concentration of drugs were added. After incubation for 72 hr, cytotoxicity was determined as described previously [17, 18] . Each value represents the average from triplicate wells ± SD. concentrations of erlotinib were added, followed by incubation for 7 days at 37 C°.
Colonies over 10 cells were counted after Giemsa staining, as described previously [19] .
Each value represents the average of duplicate dishes.
Western blot analysis
Cells were rinsed with ice-cold PBS and lysed in Triton X-100 buffer (50 mmol/L HEPES, 150 mmol/L NaCl, 50 mmol/L NaF, 1% Triton X-100, and 10% glycerol containing 5 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, 10 µg/mL aprotinin, 10 µg/mL leupeptin, and 1 mmol/L sodium orthovanadate), and cell lysates were separated by SDS-PAGE and transferred to Immobilon membranes (Millipore Corp.).
For detection of active integrinβ1, cells were plated on fibronectin-or collagen-coated dishes, and incubated with anti-active integrinβ1 antibody (HUTS-4) for 30 min at 37 C°.
Cells were then rinsed with PBS, lysed in SDS sample buffer, and bound antibody was detected by western blotting [20] . Immunoprecipitation (IP) was described in Supplementary Material and Methods.
Cell adhesion assay
For cell adhesion assay, 96 well plates were coated with collagen (10μg/well, Integrinβ1 contributes to EGFR-TKI resistance in NSCLC Trevigen) or fibronectin (5μg/well, Trevigen), and cancer cells were seeded onto the ECM components, allowed to adhere for 30 min at 37C°. Each value represents the average from triplicate trials ± SD
Quantitative real-time PCR
RNA was reverse transcribed from random hexamers using avian myeloblastosis virus reverse transcriptase (Promega). In brief, 20 μl of PCR amplification reaction mixtures contained cDNA, primer pairs (Applied Biosystems), a dual-labeled fluorogenic probe (Applied Biosystems), and Taqman Universal PCR Master Mix (Applied Biosystems). The thermal cycle conditions included maintaining the reactions at 50°C for 2 min and 95°C for 10 min, and then 40 cycles alternating between 95°C for 15 seconds and 60°C for 1 min. The relative gene expression for each sample was determined using the formula 2(−ΔCt) = 2[Ct (GAPDH) − Ct (target)], which reflected the target gene expression normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels.
Each value represents the average from triplicate trials ± SD.
Flow cytometry (FACS)
Cell suspension (10 6 Integrinβ1 contributes to EGFR-TKI resistance in NSCLC Caliber System (Becton-Dickinson).
Tumor samples
Informed consent for the use of tumor tissue specimens was obtained from patients according to the legal guidance [21, 22] . Tumor samples, Case 4 and Case 10, are collected from University Hospital, University of Occupational and Environmental Health, Japan. Tumor samples, Case RB4 and Case RB11, are from EURTAC Study in Spain. The EURTAC was approved by the institutional review board of each participating center, and written informed consent was obtained from all patients. Mutation status of EGFR (delE746-A750 and L858R) and T790M was examined by direct sequencing analysis.
K-Ras mutations were investigated by PCR-analysis [21, 22, 23] .
Immunohistochemical analysis
Expression of integrins and Src was examined by IHC staining previously described methods [23] . Anti-integrinβ1 mAb was purchased from Abcam Inc., anti-integrinα2 mAb was from Epitomics, anti-integrinα5 mAb was from Santa Cruz Biotechnology and anti-Src was from Cell Signaling Technology. The intensity of staining was scored using the following scale: no staining, 0; weak staining, +1; moderate staining, +2; and strong staining, +3, in >10% of cancer cells. 
Results

Establishment of the erlotinib-resistant subclones from PC9 cells and 11-18 cells
To isolate erlotinib-resistant subclones from PC9 cells harboring the activating EGFR delE746-A750 mutation, and 11-18 cells harboring activating EGFR L858R mutation, we cultured PC9 cells and 11-18 cells in increasing, step-wise doses of erlotinib up to 15 μM for approximately 6 months as described previously [14, 17] . We isolated a drug-resistant cell lines, PC9/ER2 and 11-18/ER2, and further established drug-resistant subclones, PC9/ER2-2 and PC9/ER2-3 from PC9/ER2 and 11-18/ER2-1 from 11-18/ER2 ( Figure 1A , Table 1 ). Growth rates between each parental cell line and resistant subclones are similar (Table 1) . Resistant subclones also manifested increased resistance to gefitinib as compared to the parental cell lines (Table 1 ). In contrast, these three resistant subclones exhibited similar sensitivities to picropodophyllin (an inhibitor of IGF1R), SU11274 (an inhibitor of Met), and cisplatin as compared to the parental cell lines (Table 1) . Neither alteration for secondary EGFR mutations (T790M, T854A, L747S and D761Y) nor hot spot activating mutation of PIK3CA was detected in resistant subclones (data not shown).
As compared to parental cell lines, all resistant subclones expressed relatively lower levels of phospho-HER2 (pHER2) ( Figure 1B ). In addition, two resistant subclones from PC9 expressed lower levels of HER2, HER3, and phospho-HER3 (pHER3). In EGFR expression was lower in 11-18/ER2-1 cells because of partial loss of mutated EGFR gene allele, as described previously [17] . The phosphorylation of EGFR (pEGFR) and Erk1/2 (pErk1/2) was similarly inhibited by erlotinib in a dose-dependent manner in parental cell lines as well as the resistant subclones. In contrast, the phosphorylation of Akt was observed even in the presence of erlotinib in the resistant subclones ( Figure 1C ).
Increased expression of β1, α2, and α5 integrins in the erlotinib-resistant subclones
We further examined the expression levels of integrins in the resistant subclones by western blot analysis. Surprisingly, all resistant subclones manifested higher levels of β1, α2, and α5 integrins than the parental cell lines. However, there were similar expression levels of αv and β4 integrins between parental cell lines and the resistant subclones ( Figure 2A ). PC9/ER2-2 and PC9/ER2-3 also exhibited higher expression levels of integrinβ1 mRNA than the PC9 cells, but 11-18/ER2-1 exhibited similar expression levels of integrinβ1 mRNA ( Figure 2B ). FACS analysis also revealed higher expression levels of membranous integrinβ1 in PC9/ER2-2 and 11-18/ER2-1 as compared to parental cell lines ( Figure 2C ). Integrinβ1 is known to dimerized with α integrin family proteins α2 and α5 [24] , and IP western blot analysis revealed that α2 or α5 integrins were co-immunoprecipitated with integrinβ1 in PC9/ER2-2 and PC9/ER2-3 cells (Supplementary Figure S1A) .
Integrins induce the activation of downstream regulatory signaling pathways by adopting a high-affinity state to interact with extracellular matrices [25] . Ligand of integrinα2β1 and integrinα5β1 are collagen and fibronectin, respectively. As shown in Figure 2D , increased activation of integrinβ1 in PC9/ER2-2 and 11-18/ER2-1 cells as compared to parental cell lines was observed in the presence of fibronectin or collagen when a specific antibody (HUTS-4) recognizing ligand-occupied integrinβ1 was used.
Furthermore, the adhesion of cells to collagen-or fibronectin-coated plates in the resistant subclones was significantly higher than that observed in parental cell lines ( Figure 2E ).
Integrinβ1 knockdown overcomes erlotinib resistance in resistant subclones
We next examined whether integrinβ1 expression was correlated with erlotinib resistance or constitutive Akt phosphorylation. Treatment with integrinβ1 siRNA almost completely suppressed the expression of integrinβ1 protein and mRNA ( Figure 3A and there were no apparent changes in the growth rates between each parental cell line and their resistant subclones upon exposure to integrinβ1 siRNA for five days (data not shown).
In resistant subclones, Integrinβ1 siRNA-treatment restored sensitivity to erlotinib ( Figure   3C ), and erlotinib treatment almost completely blocked the constitutive phosphorylation of Akt when integrinβ1 was silenced ( Figure 3D ). We further examined whether integrins α2 and α5 were also involved in the constitutive Akt phosphorylation in PC9/ER2-2 cells (Supplementary Figure S1B) . The phosphorylation of Akt was moderately inhibited by erlotinib when integrinα2 or integrinα5 was silenced in PC9/ER2-2 cells. Integrinβ1 Figure S2C) . The phosphorylation of EGFR and Erk1/2 was similarly suppressed by erlotinib in the PC9/Mock cells and the corresponding integrinβ1-overexpressing cell lines. Thus, the overexpression of integrinβ1 with integrinα2 and integrinα5 appears to be one of the mechanisms underlying acquired erlotinib resistance.
Src knockdown and dasatinib treatment suppress Akt phosphorylation and cell survival in the resistant subclones
Src protein, which interacts with PI3K, is often activated by EGFR or integrinβ1 in association with extracellular matrices [26] . Thus, we next examined whether integrinβ1 could directly induce the activation of the Src/Akt pathway and whether this pathway could be responsible for erlotinib resistance. Relatively higher expression levels Figure S3A) . Moreover, PC9/ER2-2 cells were more sensitive to dasatinib than PC9 cells (Supplementary Figure S3B) , suggesting that Src activation in the resistant subclone may sensitize those cells to the cytotoxic effects of dasatinib.
The expression of integrins in cancer cells from refractory lung tumors
We finally examined whether integrin expression could be observed in gefitinib-or erlotinib-refractory tumors. Four clinical samples were prepared from lung adenocarcinoma patients treated with gefitinib or/and erlotinib, but subsequently became Table S1 ) [21] . As shown in Supplementary Table S1 , two patients harbored L858R and two patients harbored delE746-A750. Figure 5 shows typical immunohistochemistry images from the patients.
Especially expression of integrinβ1 was increased in the post-erlotinib and post-gefitinib tumor samples with enhanced expression of integrinα2 or α5. Src expression was also enhanced after treatment, but only post-erlotinib sample of Case 10 shows lower expression of Src than pre-treatment sample. One sample, Case RB4 harboring T790M secondary mutation of EGFR, shows higher expression of integrinβ1, α2 and Src in post-gefitinib treatment. In this case, integrins overexpression might not be directory correlated with acquired resistance ( Figure 5D ). Expression of integrins and Src in four clinical samples was summarized in Supplementary Table S1 . 
Discussion
In our present study, we established erlotinib-resistant subclones from PC9 cells harboring the activating del E746-A750 EGFR mutation and 11-18 cells harboring the activating L858R EGFR mutation. We observed the following characteristics in these resistant subclones: 1) Akt was constitutively activated, and the phosphorylation of Akt was not suppressed by erlotinib in resistant subclones; 2) the expression of β1, α2 and α5 integrins was upregulated along with Src activation; 3) the knockdown of integrinβ1 restored cellular sensitivity to erlotinib and reduced Akt phosphorylation; 4) Src knockdown or dasatinib treatment effectively inhibited cell survival and reduced Akt phosphorylation in the presence or absence of erlotinib; and 5) enhanced expression of integrin β1, α2 and/or α5 was also observed in refractory tumor samples from lung cancer patients treated with gefitinib and/or erlotinib. Together, these novel findings indicate that the acquisition of erlotinib resistance is mediated by the activation of the integrinβ1/Src/Akt signaling pathway ( Figure 6 ).
Three major mechanisms including the alteration of oncogenic targets, the activation of downstream regulatory molecules, and the activation of bypass effectors, are known to contribute to acquired resistance to molecularly targeted drugs in cancer cells [7] .
The present study suggests that the acquisition of erlotinib resistance is attributable to the 
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Integrinβ1 contributes to EGFR-TKI resistance in NSCLC activation of an integrinβ1-driven bypass signaling pathway. Furthermore, the study by Ju et al. [27] was previously reported that transfection with integrinβ1 cDNA protected PC9 cells from apoptosis in response to gefitinib treatment. However, this study did not evaluate how integrinβ1 overexpression renders lung cancer cells resistant to EGFR-TKIs.
Our study demonstrated that transfection with integrinβ1 slightly induced erlotinib resistance in PC9 cells (Supplementary Figure S2) , and in these integrinβ1-overexpressing cell lines, there was no enhanced expression of integrinα2 or α5, suggesting that the co-activation of β1/α2 and/or β1/α5 integrins is required for the acquisition of increased erlotinib resistance via the integrinβ1 signaling pathway.
The interactions between cancer cells and the extracellular matrices often reduce the sensitivity to anticancer agents, including gefitinib [28] [29] [30] [31] , and the expression of integrin family proteins plays an important role in the malignant progression of cancers [32] [33] [34] . The cell proliferation rates were similar between parental cell lines and the resistant subclones, but the adhesion to collagen or fibronectin was much higher in the resistant subclones. Integrinβ1 thus appears to be responsible for not only the acquisition of erlotinib resistance but also for cell adhesion activity.
In the current study, we observed constitutive phosphorylation of Akt even in the presence of erlotinib in resistant subclones. This phosphorylation was markedly 
Integrinβ1 contributes to EGFR-TKI resistance in NSCLC suppressed by erlotinib upon integrinβ1 knockdown, and cell sensitivity to erlotinib was restored by integrinβ1 knockdown. These data strongly suggest an essential role for integrinβ1/α2 and/or integrinβ1/α5 in the constitutive activation of Akt and in the drug resistance in the resistant subclones. Our study also sought to understand how integrinβ1 promotes Akt phosphorylation and the acquisition of drug resistance. Of the potentially relevant molecules, Src is known to be a downstream regulator of EGFR and/or integrins, and it plays an essential role in the survival of lung cancer cells [35, 36] . Src is also responsible for the acquisition of resistance to EGFR-targeted drugs [37, 38] 
Integrinβ1 contributes to EGFR-TKI resistance in NSCLC 22 [39] . We suggest that Src is one of the effective target for lung cancer therapeutics.
We also examined whether integrinβ1, together with integrinα2 or integrinα5, was expressed in lung cancer refractory to gefitinib and/or erlotinib. These results demonstrated increased expression of β1, α2 and/or α5 integrins in four refractory tumors following treatment with gefitinib and/or erlotinib ( Figure 5 , and Supplementary Figure   S1 ). Enhanced expression of integrinβ1 and α2 were also observed in case RB4 harbored T790M secondary EGFR mutation ( Figure 5D ). It remains to be further studied whether the enhanced expression of integrinβ1, α2 and Src is closely correlated with T790M mutation. Recently, integrin family targeted drugs are focused on cancer therapeutics. For example, anti-integrinα5β1 antibody (volocixmab) is performed on phase II clinical trials for several cancers including NSCLC [40, 41] . Further study should be also required whether these integrin-targeted drugs could be useful to overcome drug resistance in patients with NSCLC.
In conclusion, the acquisition of erlotinib resistance in our erlotinib-resistant subclones was attributable to the overexpression of integrinβ1/α2/α5, which resulted in the activation of an integrin/Src/Akt pathway. This relationship between integrin expression and Src activity may be useful for the development of both personalized therapeutics involving EGFR-TKIs and for circumventing drug resistance in patients with NSCLC. 
